Exondys 51

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared as high as $63.73 following a controversial decision by the U.S. Food and Drug Administration to approve the company's treatment of Duchenne muscular dystrophy in September 2016. Since the FDA's announcement, the stock has lost more than half...

There's nothing better from a public relations standpoint than whipping the public into a frenzy over a new product or service. Several companies made a big splash this year with big announcements, events and launches. Here's a look at how the stocks performed after the initial hype...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has taken quite a disappointing round-trip for shareholders since the stock jumped from $27.99 to $63.73 in a matter of days back in September. On September 19, the FDA granted accelerated approval for Sarepta’s Exondys 51, which became the first...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares nearly doubled back in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, after conducting a round of due diligence by talking to private payers and other experts, Jefferies analyst Gena Wang...

After agreeing to cover Sarepta Therapeutics Inc (NASDAQ: SRPT)’s controversial Duchenne muscular dystrophy drug Exondys 51, insurer Aetna Inc (NYSE: AET) has released a new clinical policy bulletin describing the conditions under which it deems the drug medically necessary. Aetna now...

Back on October 6, Duchenne Muscular Dystrophy (DMD) treatment advocate Jenn McNary announced on Twitter that Humana Inc (NYSE: HUM) had approved 100 percent coverage for a patient wanting access to Sarepta Therapeutics Inc (NASDAQ: SRPT) muscular dystrophy drug eteplirsen - marketed as EXONDYS...

Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the company's therapy for the treatment of Duchenne muscular dystrophy (DMD). There are three reasons investors should take a "more cautious view" on...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares nearly doubled in September after the FDA granted accelerated approval for the company’s first drug, EXONDYS 51. However, Credit Suisse analyst Alethia Young believes Sarepta is just getting started. Credit Suisse is anticipating the first...

Commenting on the U.S. commercial launch of Sarepta Therapeutics Inc’s (NASDAQ: SRPT) Exondys 51, Wedbush’s Heather Behanna said that the initial adoption would likely be rapid although logistical challenges may continue. The analyst maintained an Outperform rating on Sarepta, while...

The craze for Sarepta Therapeutics Inc (NASDAQ: SRPT) shares continued into its second day, gaining about 15 percent on Tuesday. The stock nearly doubled from the $28.15 recorded on September 16. Two catalysts likely responsible for this rally include the FDA approval for the company's Duchenne...

Sarepta Therapeutics Inc (NASDAQ: SRPT) hosted a conference call Tuesday to discuss its newly approved drug, Exondys 51 (eteplirsen) injection, which happens to be the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Sarepta said Exondys 51 will be available in a...